Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1038/nrd1468
10.1038/nrd1468 · External reference
10.1016/j.drudis.2015.05.001
10.1016/j.drudis.2015.05.001 · External reference
Drug repositioning: a brief overview
10.1111/jphp.13273 · 2020 · External reference
10.1016/j.ddstr.2011.10.002
10.1016/j.ddstr.2011.10.002 · External reference
10.1038/nrclinonc.2015.169
10.1038/nrclinonc.2015.169 · External reference
10.1093/eurheartj/ehw051
10.1093/eurheartj/ehw051 · External reference
The promise and challenges of drug repurposing in psychiatry
10.1002/wps.20481 · 2018 · External reference
10.1038/s41564-019-0357-1
10.1038/s41564-019-0357-1 · External reference
CNS repurposing – Potential new uses for old drugs: Examples of screens for Alzheimer's disease
2019 · External reference
Drug Repurposing for Rare Diseases: A Role for Academia
10.3389/fphar.2021.746987 · 2021 · External reference
10.1016/j.tips.2016.01.007
10.1016/j.tips.2016.01.007 · External reference
Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management
10.3389/fendo.2017.00006 · 2017 · External reference
10.1038/nrdp.2015.19
10.1038/nrdp.2015.19 · External reference
Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy
10.1200/jco.2016.67.4044 · 2016 · External reference
Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience
10.1016/bs.pbr.2019.10.008 · 2020 · External reference
Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease
10.2337/db14-0287 · 2014 · External reference
10.1161/circresaha.110.223545
10.1161/circresaha.110.223545 · External reference
10.1056/nejmoa1504720
10.1056/nejmoa1504720 · External reference
10.1016/j.diabres.2021.109119
10.1016/j.diabres.2021.109119 · External reference
Current prevalence of Type 1 and Type 2 diabetes in adults and children in the UK
10.1111/dme.12791 · 2015 · External reference
Incidence of type 1 and type 2 diabetes in adults aged 30–49 years: the population-based registry in the province of Turin
2005 · External reference
10.1038/emm.2016.7
10.1038/emm.2016.7 · External reference
10.1111/obr.12298
10.1111/obr.12298 · External reference
Microvascular Complications of Type 2 Diabetes Mellitus
10.2174/1570161117666190502103733 · 2020 · External reference
Macrovascular Complications of Type 2 Diabetes Mellitus
10.2174/1570161117666190405165151 · 2020 · External reference
10.1038/nrd.2018.168
10.1038/nrd.2018.168 · External reference
10.1038/nbt1284
10.1038/nbt1284 · External reference
10.3389/fphar.2018.00006
10.3389/fphar.2018.00006 · External reference
10.1016/j.drudis.2013.07.001
10.1016/j.drudis.2013.07.001 · External reference
In silico methods for drug repurposing and pharmacology
10.1002/wsbm.1337 · 2016 · External reference
Data analysis and data mining: current issues in biomedical informatics
10.3414/me11-06-0002 · 2011 · External reference
10.1038/s41573-019-0024-5
10.1038/s41573-019-0024-5 · External reference
10.1007/s11095-016-2029-7
10.1007/s11095-016-2029-7 · External reference
10.1002/minf.201501008
10.1002/minf.201501008 · External reference
10.1109/tcbb.2021.3091814
10.1109/tcbb.2021.3091814 · External reference
DeepAffinity: interpretable deep learning of compound-protein affinity through unified recurrent and convolutional neural networks
10.1093/bioinformatics/btz111 · 2019 · External reference
10.1016/j.neunet.2014.09.003
10.1016/j.neunet.2014.09.003 · External reference
Comparison of Deep Learning With Multiple Machine Learning Methods and Metrics Using Diverse Drug Discovery Data Sets
10.1021/acs.molpharmaceut.7b00578 · 2017 · External reference
10.1021/acs.molpharmaceut.6b00248
10.1021/acs.molpharmaceut.6b00248 · External reference
10.1093/bib/bbaa003
10.1093/bib/bbaa003 · External reference
Recent Advances in the Machine Learning-Based Drug-Target Interaction Prediction
10.2174/1389200219666180821094047 · 2019 · External reference
Deep learning for drug repurposing: Methods, databases, and applications. WIREs Computational Molecular
2022 · External reference
Deep learning in target prediction and drug repositioning: Recent advances and challenges
2021 · External reference
Unresolved reference
External reference
10.1093/bib/bbt056
10.1093/bib/bbt056 · External reference
Comprehensive Survey of Recent Drug Discovery Using Deep Learning
2021 · External reference
10.1109/tpami.2013.50
10.1109/tpami.2013.50 · External reference
10.1016/j.drudis.2020.03.003
10.1016/j.drudis.2020.03.003 · External reference
10.1021/ci00062a008
10.1021/ci00062a008 · External reference
10.1021/ci00057a005
10.1021/ci00057a005 · External reference
10.1021/acs.jmedchem.0c00385
10.1021/acs.jmedchem.0c00385 · External reference
Graph representation learning for structural proteomics
10.1042/etls20210225 · 2021 · External reference
10.1101/610444
10.1101/610444 · External reference
Machine Learning for Drug-Target Interaction Prediction
2018 · External reference
Machine-learning approaches in drug discovery: methods and applications
10.1016/j.drudis.2014.10.012 · 2015 · External reference
10.1016/b978-0-12-816125-8.00024-9
10.1016/b978-0-12-816125-8.00024-9 · External reference
10.1093/bib/bbz157
10.1093/bib/bbz157 · External reference
10.1039/c9sc04336e
10.1039/c9sc04336e · External reference
10.1021/acs.jproteome.6b00618
10.1021/acs.jproteome.6b00618 · External reference
Coupled matrix-matrix and coupled tensor-matrix completion methods for predicting drug-target interactions
10.1093/bib/bbaa025 · 2021 · External reference
Unresolved reference
External reference
MolAICal: a soft tool for 3D drug design of protein targets by artificial intelligence and classical algorithm
10.1093/bib/bbaa161 · 2021 · External reference
Application advances of deep learning methods for de novo drug design and molecular dynamics simulation
10.1002/wcms.1581 · 2022 · External reference
Matrix Factorization-based Technique for Drug Repurposing Predictions
10.1109/jbhi.2020.2991763 · 2020 · External reference
Hospitalisations and emergency department visits due to drug-drug interactions: a literature review
10.1002/pds.1351 · 2007 · External reference
Predicting adverse drug events from personal health messages
2011 · External reference
10.1093/bib/bbz087
10.1093/bib/bbz087 · External reference
Predicting drug-drug interactions by graph convolutional network with multi-kernel
2021 · External reference
10.1111/cbdd.12378
10.1111/cbdd.12378 · External reference
A machine learning framework for predicting drug-drug interactions
10.1038/s41598-021-97193-8 · 2021 · External reference
DDIGIP: predicting drug-drug interactions based on Gaussian interaction profile kernels
10.1186/s12859-019-3093-x · 2019 · External reference
Prediction of the Drug-Drug Interaction Types with the Unified Embedding Features from Drug Similarity Networks
10.3389/fphar.2021.794205 · 2021 · External reference
Learning from low-rank multimodal representations for predicting disease-drug associations
10.1186/s12911-021-01648-x · 2021 · External reference
Computational drug repositioning based on multi-similarities bilinear matrix factorization
10.1093/bib/bbaa267 · 2021 · External reference
Predicting drug-disease interactions by semi-supervised graph cut algorithm and three-layer data integration
10.1186/s12920-017-0311-0 · 2017 · External reference
10.3322/caac.20078
10.3322/caac.20078 · External reference
Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes
10.1186/bcr3089 · 2012 · External reference
10.1016/j.ctrv.2012.04.007
10.1016/j.ctrv.2012.04.007 · External reference
10.1016/j.freeradbiomed.2010.09.006
10.1016/j.freeradbiomed.2010.09.006 · External reference
10.4103/jrms.jrms_242_19
10.4103/jrms.jrms_242_19 · External reference
10.1158/1940-6207.capr-10-0157
10.1158/1940-6207.capr-10-0157 · External reference
The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis
10.1111/dom.12267 · 2014 · External reference
The effect of metformin on mortality following cancer among patients with diabetes
10.1158/1055-9965.epi-14-0327 · 2014 · External reference
Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies
10.1038/srep10147 · 2015 · External reference
Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis
10.18632/oncotarget.13762 · 2017 · External reference
10.1016/j.metabol.2013.01.014
10.1016/j.metabol.2013.01.014 · External reference
Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders
10.1158/1940-6207.capr-13-0424 · 2014 · External reference
10.1371/journal.pone.0033411
10.1371/journal.pone.0033411 · External reference
Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis
10.1634/theoncologist.2011-0462 · 2012 · External reference
10.1007/s00125-012-2653-7
10.1007/s00125-012-2653-7 · External reference
10.1016/j.canep.2012.12.009
10.1016/j.canep.2012.12.009 · External reference
The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose-response of randomized clinical trials
10.1007/s12094-019-02108-9 · 2020 · External reference
Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression
10.1007/s00384-020-03676-x · 2020 · External reference
Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes
10.1016/j.aohep.2019.11.008 · 2020 · External reference
The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis
10.2174/1381612827666210315144821 · 2021 · External reference
Relationships are between metformin use and survival in pancreatic cancer patients concurrent with diabetes: A systematic review and meta-analysis
10.1097/md.0000000000021687 · 2020 · External reference
Prognostic significance of metformin treatment in endometrial cancer: a meta-analysis
10.31083/ph.2020.0346 · 2020 · External reference
The effect of metformin on lung cancer risk and survival in patients with type 2 diabetes mellitus: A meta-analysis
10.1111/jcpt.13167 · 2020 · External reference
The role of metformin on lung cancer survival: the first systematic review and meta-analysis of observational studies and randomized clinical trials
10.1007/s00432-021-03728-x · 2021 · External reference
10.1080/13543784.2017.1333104
10.1080/13543784.2017.1333104 · External reference
Incident Hepatocellular Carcinoma Risk in Patients Treated with a Sulfonylurea: A Nationwide, Nested, Case-Control Study
10.1038/s41598-019-44447-1 · 2019 · External reference
Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry
10.1016/j.diabres.2010.08.022 · 2010 · External reference
Sulphonylureas and cancer: a case-control study
10.1007/s00592-008-0083-2 · 2009 · External reference
10.1016/j.bcp.2008.09.009
10.1016/j.bcp.2008.09.009 · External reference
Glyburide attenuates B(a)p and LPS-induced inflammation-related lung tumorigenesis in mice
10.1002/tox.23293 · 2021 · External reference
Liraglutide inhibits the proliferation and promotes the apoptosis of MCF-7 human breast cancer cells through downregulation of microRNA-27a expression
2018 · External reference
Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line
10.1016/j.ejphar.2020.173102 · 2020 · External reference
Exendin-4 does not modify growth or apoptosis of human colon cancer cells
2017 · External reference
Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells
10.1210/en.2011-1201 · 2011 · External reference
Exenatide modulates tumor-endothelial cell interactions in human ovarian cancer cells
10.1530/ec-17-0294 · 2017 · External reference
Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer
10.1186/s12885-018-4570-8 · 2018 · External reference
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials
10.1111/dom.12926 · 2017 · External reference
GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials
10.1007/s12020-020-02223-6 · 2020 · External reference
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis
10.1016/j.rbmo.2019.04.017 · 2019 · External reference
10.1002/ijc.31193
10.1002/ijc.31193 · External reference
Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway
10.1016/j.biopha.2020.110821 · 2020 · External reference
10.1007/s13340-021-00494-6
10.1007/s13340-021-00494-6 · External reference
Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter-1 and lactate dehydrogenase A
2020 · External reference
Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes
10.18632/oncotarget.12137 · 2017 · External reference
Sitagliptin and oral cancer risk in type 2 diabetes patients
10.18632/oncotarget.18239 · 2017 · External reference
Sitagliptin May Reduce Breast Cancer Risk in Women With Type 2 Diabetes
10.1016/j.clbc.2016.11.002 · 2017 · External reference
Repositioning of Hypoglycemic Drug Linagliptin for Cancer Treatment
10.3389/fphar.2020.00187 · 2020 · External reference
Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma-associated antigen-A3 expression through Yes-associated protein inactivation
10.1002/cam4.3024 · 2020 · External reference
10.1007/s00592-020-01479-8
10.1007/s00592-020-01479-8 · External reference
Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats
10.1002/ijc.28260 · 2013 · External reference
10.1007/s10585-015-9736-z
10.1007/s10585-015-9736-z · External reference
Type 2 Diabetes Mellitus and Alzheimer’s Disease: Role of Insulin Signalling and Therapeutic Implications
10.3390/ijms19113306 · 2018 · External reference
10.3233/jpd-191900
10.3233/jpd-191900 · External reference
10.1016/j.pneurobio.2016.10.001
10.1016/j.pneurobio.2016.10.001 · External reference
The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of
2020 · External reference
Diabetes drugs in the fight against Alzheimer's disease
10.1016/j.arr.2019.100936 · 2019 · External reference
10.1016/j.bbadis.2016.08.018
10.1016/j.bbadis.2016.08.018 · External reference
10.1111/ejn.15502
10.1111/ejn.15502 · External reference
10.1002/14651858.cd012990.pub2
10.1002/14651858.cd012990.pub2 · External reference
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
10.1016/s0140-6736(17)31585-4 · 2017 · External reference
Exenatide and the treatment of patients with Parkinson's disease
10.1172/jci68295 · 2013 · External reference
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study
10.1136/bmjopen-2020-047993 · 2021 · External reference
Neuroprotective effects of liraglutide against inflammation through the AMPK/NF-κB pathway in a mouse model of Parkinson's disease
2021 · External reference
Insulin resistance is a cardiovascular risk factor in humans
10.1016/j.dsx.2019.02.023 · 2019 · External reference
Diabetes and lipid metabolism
10.1007/s42000-018-0014-8 · 2018 · External reference
10.1016/j.molmet.2013.11.006
10.1016/j.molmet.2013.11.006 · External reference
Repurposing Antidiabetic Drugs for Cardiovascular Disease
10.3389/fphys.2020.568632 · 2020 · External reference
10.1056/nejmoa1611925
10.1056/nejmoa1611925 · External reference
10.1161/circulationaha.118.038868
10.1161/circulationaha.118.038868 · External reference
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
10.1136/bmj.m4573 · 2021 · External reference
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
10.1016/s2213-8587(19)30249-9 · 2019 · External reference
Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
10.1161/circresaha.117.311588 · 2018 · External reference
10.1161/circulationaha.114.010389
10.1161/circulationaha.114.010389 · External reference
10.2337/dci18-0033
10.2337/dci18-0033 · External reference
